These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26608890)

  • 21. UCSF Small Molecule Discovery Center: innovation, collaboration and chemical biology in the Bay Area.
    Arkin MR; Ang KK; Chen S; Davies J; Merron C; Tang Y; Wilson CG; Renslo AR
    Comb Chem High Throughput Screen; 2014 May; 17(4):333-42. PubMed ID: 24661212
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The intellectual property management for data sharing in a German liver cancer research network.
    He S; Ganzinger M; Knaup P
    Stud Health Technol Inform; 2012; 180():891-5. PubMed ID: 22874321
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving models of collaborative drug discovery: managing intellectual capital assets.
    Allarakhia M
    Expert Opin Drug Discov; 2018 Jun; 13(6):473-476. PubMed ID: 29569503
    [No Abstract]   [Full Text] [Related]  

  • 24. [The discovery process in the pharmaceutical industry].
    Scatton B
    J Soc Biol; 2009; 203(3):249-69. PubMed ID: 19833071
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug Target Identification and Validation: Global Pharmaceutical Industry Experts on Challenges, Best Strategies, Innovative Precompetitive Collaboration Concepts, and Future Areas of Industry Precompetitive Research and Development.
    Bergauer T; Ruppert T; Essioux L; Spleiss O
    Ther Innov Regul Sci; 2016 Nov; 50(6):769-776. PubMed ID: 30231745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines.
    Wang N; Lipworth WL; Ritchie JE; Williams KM; Day RO
    Intern Med J; 2011 Apr; 41(4):314-20. PubMed ID: 20403068
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The European Lead Factory: A Blueprint for Public-Private Partnerships in Early Drug Discovery.
    Karawajczyk A; Orrling KM; de Vlieger JS; Rijnders T; Tzalis D
    Front Med (Lausanne); 2016; 3():75. PubMed ID: 28154815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration.
    Wagner JA; Prince M; Wright EC; Ennis MM; Kochan J; Nunez DJ; Schneider B; Wang MD; Chen Y; Ghosh S; Musser BJ; Vassileva MT
    Clin Pharmacol Ther; 2010 May; 87(5):539-42. PubMed ID: 20407460
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Critical Path Institute's approach to precompetitive sharing and advancing regulatory science.
    Woosley RL; Myers RT; Goodsaid F
    Clin Pharmacol Ther; 2010 May; 87(5):530-3. PubMed ID: 20407457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. European Lead Factory hits its stride.
    Kingwell K
    Nat Rev Drug Discov; 2016 Apr; 15(4):221-2. PubMed ID: 27032822
    [No Abstract]   [Full Text] [Related]  

  • 31. Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery.
    Barnes MR; Harland L; Foord SM; Hall MD; Dix I; Thomas S; Williams-Jones BI; Brouwer CR
    Nat Rev Drug Discov; 2009 Sep; 8(9):701-8. PubMed ID: 19609266
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Racing to define pharmaceutical R&D external innovation models.
    Wang L; Plump A; Ringel M
    Drug Discov Today; 2015 Mar; 20(3):361-70. PubMed ID: 25448753
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The future is much closer collaboration between the pharmaceutical industry and academic medical centers.
    Vallance P; Williams P; Dollery C
    Clin Pharmacol Ther; 2010 May; 87(5):525-7. PubMed ID: 20407455
    [No Abstract]   [Full Text] [Related]  

  • 34. Fragment-based hit identification: thinking in 3D.
    Morley AD; Pugliese A; Birchall K; Bower J; Brennan P; Brown N; Chapman T; Drysdale M; Gilbert IH; Hoelder S; Jordan A; Ley SV; Merritt A; Miller D; Swarbrick ME; Wyatt PG
    Drug Discov Today; 2013 Dec; 18(23-24):1221-7. PubMed ID: 23906694
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Requirements for the license-out of drug candidates to pharmaceutical companies].
    Tawara S; Kobayashi N; Arai H; Masumi S; Itoh S; Nakahara Y; Morimoto N; Itano Y; Yamaguchi T; Niwa K; Seki J; Nakamura K
    Nihon Yakurigaku Zasshi; 2014 Apr; 143(4):198-202. PubMed ID: 24717609
    [No Abstract]   [Full Text] [Related]  

  • 36. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
    Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
    Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Universities shun Europe's drug initiative.
    Gilbert N
    Nature; 2010 Jul; 466(7304):306-7. PubMed ID: 20631770
    [No Abstract]   [Full Text] [Related]  

  • 38. Big pharma screening collections: more of the same or unique libraries? The AstraZeneca-Bayer Pharma AG case.
    Kogej T; Blomberg N; Greasley PJ; Mundt S; Vainio MJ; Schamberger J; Schmidt G; Hüser J
    Drug Discov Today; 2013 Oct; 18(19-20):1014-24. PubMed ID: 23127858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Translational informatics: an industry perspective.
    Cantor MN
    J Am Med Inform Assoc; 2012; 19(2):153-5. PubMed ID: 22237867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Collaborative approaches to anticancer drug discovery and development: a Cancer Research UK perspective.
    Williams RJ; Walker I; Takle AK
    Drug Discov Today; 2012 Mar; 17(5-6):185-7. PubMed ID: 22314099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.